Papers
1
Total Citations
62
H-Index
1
About
Dr. Xiubao Ren is a leading oncologist whose research focuses on the immunotherapy and multidisciplinary treatment of thoracic malignancies, particularly esophageal squamous cell carcinoma (ESCC). His most impactful work centers on pioneering neoadjuvant immunotherapy strategies for locally advanced, resectable ESCC. Dr. Ren is the principal investigator of the landmark Keystone-001 trial, a prospective, single-arm, phase-II study that investigates the safety and efficacy of combining pembrolizumab with chemotherapy (paclitaxel and cisplatin) before surgery. This protocol, which has garnered 62 citations, addresses a critical unmet need in China, where over 50% of global ESCC cases occur. By exploring this novel neoadjuvant approach, Dr. Ren aims to improve pathological complete response rates and long-term survival for patients with stage III disease. His work bridges the gap between standard chemoradiation and modern immunotherapy, offering a potential new standard of care. Through his rigorous clinical trial design and focus on translating immunology into practice, Dr. Ren is shaping the future of esophageal cancer treatment and improving outcomes for high-risk patient populations.
Research Focus
Key Achievements
Top Papers
- 1